Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caflanone + HLNT-06
- Development stage
- Preclinical
- Lead developer
- Flavocure Biotech
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal, Intratumoral
01
Overview
Caflanone + HLNT-06 is a preclinical-stage small-molecule drug candidate being developed by Flavocure Biotech, in partnership with Baylor College of Medicine, for the treatment of central nervous system (CNS) diseases. Caflanone (also known as FBL-03G or HLNT-06) is a synthetic, non-cannabinoid flavonoid derivative designed as the unnatural isomer of cannflavin B, a natural metabolite found in Cannabis sativa. The drug's therapeutic mechanism involves the dual inhibition of macrophage colony-stimulating factor 1 receptor (CSF1R) and casein kinase II (CK2), both of which are key regulators of neuroinflammation and microglial activation. While the broader Caflanone platform has received FDA Orphan Drug Designation and IND clearance for pancreatic cancer, the CNS-focused program remains in preclinical development.
- Other names
- CaflanoneFBL 03GFBL03GFBL-03G
02
Targets
CK2 (Casein kinase II subunit alpha)CSF1R (Macrophage colony-stimulating factor receptor)KRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on Caflanone + HLNT-06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caflanone + HLNT-06.